Cogent Biosciences, Inc. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
Cogent Biosciences, Inc. (COGT) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of -$2.58 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-10
- Cogent Biosciences, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was $7.62M, a 34.13% increase year-over-year.
- Cogent Biosciences, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was -$10.20M.
- Cogent Biosciences, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was $9.10M, a 60.75% increase year-over-year.
- Cogent Biosciences, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was $4.57M, a 34.01% decline year-over-year.
- Cogent Biosciences, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was $10.69M, a 33.03% decline from fiscal 2024.
- Cogent Biosciences, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was $15.96M, a 95.30% increase from fiscal 2023.
- Cogent Biosciences, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was $8.17M, a 14.77% decline from fiscal 2022.
- Cogent Biosciences, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2022 was $9.59M, a 179.39% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$2.58M 10-Q · filed 2026-08-10 | $6.52M derived: sum of 3 quarters · filed 2026-08-10 | $11.08M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$10.20M 10-Q · filed 2026-05-05 | -$1.10M derived: sum of 2 quarters · filed 2026-05-05 | $3.46M derived: sum of 3 quarters · filed 2026-05-05 | $9.14M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $9.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $13.66M derived: sum of 2 quarters · filed 2026-02-17 | $19.34M derived: sum of 3 quarters · filed 2026-08-10 | $10.69M 10-K · filed 2026-02-17 |
| 2025-09-30 | $4.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $10.24M derived: sum of 2 quarters · filed 2026-08-10 | $1.59M 10-Q · filed 2025-11-07 | $7.25M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $5.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$2.98M 10-Q · filed 2026-08-10 | $2.68M derived: sum of 3 quarters · filed 2026-08-10 | $9.60M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$8.66M 10-Q · filed 2026-05-05 | -$3.00M derived: sum of 2 quarters · filed 2026-05-05 | $3.92M derived: sum of 3 quarters · filed 2026-05-05 | $14.02M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $5.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $12.58M derived: sum of 2 quarters · filed 2026-02-17 | $22.68M derived: sum of 3 quarters · filed 2026-02-17 | $15.96M 10-K · filed 2026-02-17 |
| 2024-09-30 | $6.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $17.02M derived: sum of 2 quarters · filed 2025-11-07 | $10.29M 10-Q · filed 2025-11-07 | $12.92M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-06-30 | $10.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $3.38M 10-Q · filed 2025-08-05 | $6.00M derived: sum of 3 quarters · filed 2026-02-17 | $12.26M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-03-31 | -$6.72M 10-Q · filed 2025-05-06 | -$4.09M derived: sum of 2 quarters · filed 2026-02-17 | $2.16M derived: sum of 3 quarters · filed 2026-02-17 | $4.01M derived: sum of 4 quarters · filed 2026-02-17 |
| 2023-12-31 | $2.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $8.88M derived: sum of 2 quarters · filed 2026-02-17 | $10.73M derived: sum of 3 quarters · filed 2026-02-17 | $8.17M 10-K · filed 2026-02-17 |
| 2023-09-30 | $6.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $8.10M derived: sum of 2 quarters · filed 2024-11-12 | $5.54M 10-Q · filed 2024-11-12 | $9.35M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $1.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$708.00K 10-Q · filed 2024-08-06 | $3.10M derived: sum of 3 quarters · filed 2025-02-25 | $5.71M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | -$2.56M 10-Q · filed 2024-05-07 | $1.25M derived: sum of 2 quarters · filed 2025-02-25 | $3.86M derived: sum of 3 quarters · filed 2025-02-25 | $6.83M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $3.81M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $6.41M derived: sum of 2 quarters · filed 2025-02-25 | $9.39M derived: sum of 3 quarters · filed 2025-02-25 | $9.59M 10-K · filed 2025-02-25 |
| 2022-09-30 | $2.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $5.58M derived: sum of 2 quarters · filed 2023-11-07 | $5.78M 10-Q · filed 2023-11-07 | $6.94M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | $2.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $3.17M 10-Q · filed 2023-08-08 | $4.34M derived: sum of 3 quarters · filed 2024-02-26 | $4.94M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | $199.00K 10-Q · filed 2023-05-09 | $1.36M derived: sum of 2 quarters · filed 2024-02-26 | $1.96M derived: sum of 3 quarters · filed 2024-02-26 | $5.66M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | $1.16M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $1.76M derived: sum of 2 quarters · filed 2024-02-26 | $5.46M derived: sum of 3 quarters · filed 2024-02-26 | $3.43M 10-K · filed 2024-02-26 |
| 2021-09-30 | $602.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $4.30M derived: sum of 2 quarters · filed 2022-11-14 | $2.27M 10-Q · filed 2022-11-14 | $1.51M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $3.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $1.67M 10-Q · filed 2022-08-09 | $910.00K derived: sum of 3 quarters · filed 2022-08-09 | $818.00K derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$2.03M 10-Q · filed 2022-05-10 | -$2.79M derived: sum of 2 quarters · filed 2022-05-10 | -$2.88M derived: sum of 3 quarters · filed 2022-05-10 | -$3.37M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | -$756.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | -$848.00K derived: sum of 2 quarters · filed 2022-03-15 | -$1.34M derived: sum of 3 quarters · filed 2022-03-15 | -$2.35M 10-K · filed 2022-03-15 |
| 2020-09-30 | -$92.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$588.00K derived: sum of 2 quarters · filed 2021-11-10 | -$1.60M 10-Q · filed 2021-11-10 | -$1.00M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | -$496.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | -$1.50M 10-Q · filed 2021-08-16 | -$911.00K derived: sum of 3 quarters · filed 2021-08-16 | -$302.00K derived: sum of 4 quarters · filed 2021-08-16 |
| 2020-03-31 | -$1.01M 10-Q · filed 2021-05-12 | -$415.00K derived: sum of 2 quarters · filed 2021-05-12 | $194.00K derived: sum of 3 quarters · filed 2021-05-12 | $56.00K derived: sum of 4 quarters · filed 2021-05-12 |
| 2019-12-31 | $593.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $1.20M derived: sum of 2 quarters · filed 2021-03-16 | $1.06M derived: sum of 3 quarters · filed 2021-03-16 | $1.76M 10-K · filed 2021-03-16 |
| 2019-09-30 | $609.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $471.00K derived: sum of 2 quarters · filed 2020-11-09 | $1.17M 10-Q · filed 2020-11-09 | $1.04M derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | -$138.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | $558.00K 10-Q · filed 2020-08-11 | $434.00K derived: sum of 3 quarters · filed 2020-08-11 | $3.21M derived: sum of 4 quarters · filed 2020-08-11 |
| 2019-03-31 | $696.00K 10-Q · filed 2020-05-11 | $572.00K derived: sum of 2 quarters · filed 2020-05-11 | $3.35M derived: sum of 3 quarters · filed 2020-05-11 | $4.49M derived: sum of 4 quarters · filed 2020-05-11 |
| 2018-12-31 | -$124.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | $2.66M derived: sum of 2 quarters · filed 2020-03-26 | $3.79M derived: sum of 3 quarters · filed 2020-03-26 | $2.88M 10-K · filed 2020-03-26 |
| 2018-09-30 | $2.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $3.92M derived: sum of 2 quarters · filed 2019-11-12 | $3.01M 10-Q · filed 2019-11-12 | $3.46M derived: sum of 4 quarters · filed 2019-11-12 |
| 2018-06-30 | $1.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-12 | $227.00K 10-Q · filed 2019-08-12 | $681.00K derived: sum of 3 quarters · filed 2019-08-12 | |
| 2018-03-31 | -$908.00K 10-Q · filed 2019-05-13 | -$454.00K derived: sum of 2 quarters · filed 2019-05-13 | ||
| 2017-12-31 | $454.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-28 | $1.17M 10-K · filed 2019-03-28 | ||
| 2017-09-30 | $714.00K 10-Q · filed 2018-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |